


Specification

The present invention is related to 1-O-alkyl-3-amino-propan-1.2-diol-2-O-phospholipids, processes for producing the same and their use as active agents in drugs, in particular for the treatment of high blood pressure, atherosclerosis and asthma as well as for their application with diseases of the immuno system and for the treatment of cancer.

The 1-O-alkyl-3-amino-propan-1.2-diol-2-O-phospholipids according to the present invention correspond to the formula I



wherein

R^1 is a saturated or unsaturated, straight-chain or branched alkyl group with 10 to 20 carbon atoms,

15 R^2 , R^3 and R^4 which may be the same or different, represent hydrogen or a lower alkyl group with 1 to 4 carbon atoms,

20 R^5 and R^6 which may be the same or different, represent hydrogen or the group $-\text{A}-\text{C}_m\text{H}_{2m}-\text{R}^7$ or $-\text{A}-\text{C}_m\text{H}_{2m-2}-\text{R}^7$,

R^7 is hydrogen, unsubstituted phenyl or phenyl substituted by a C_{1-3} -alkyl, C_{1-3} -alkoxy, trifluoromethyl group, or a halogen atom,

25 A is a bond, $-\text{CO}-$, $-\text{COO}-$ or $-\text{CONR}^8-$,
 R^8 is hydrogen or C_{1-4} -alkyl,

m is a numeral from 0 to 20 and

n is a numeral from 2 to 4.

Preferred are those compounds of formula I wherein R^1 is a saturated straight-chained alkyl group with 10 to 20 carbon atoms or an unsaturated straight-chained alkyl group with 1 or 2 double bonds and 10 to 20 carbon atoms, R^2 , R^3 and R^4 which may be the same or different from each other, represent hydrogen or a methyl group, R^5 and R^6 which may be the same or different from each other, represent hydrogen or the group $-A-(CH_2)_m-R^7$, R^7 is hydrogen, unsubstituted phenyl or phenyl substituted by a methyl, methoxy or trifluoromethyl group or a halogen atom, A represents a bond, $-CO-$, $-COO-$ or $-CONR^8-$, R^8 is hydrogen or C_{1-4} -alkyl, m is an integer from 0 to 20, if R^7 is hydrogen, or is an integer from 0 to 2, if R^7 is phenyl unsubstituted or substituted as indicated, and n is 2. Most preferred under those compounds are the compounds of formula I wherein R^1 is a saturated straight-chained alkyl group having from 10 to 20 carbon atoms while R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , m and n have the same meaning as indicated in connection with the preferred group of compounds.

Compounds according to the present invention are for instance:

3-Amino-1-0-decyl-propan-1.2-diol-2-0-phosphocholine
 3-Amino-1-0-undecyl-propan-1.2-diol-2-0-phosphocholine
 3-Amino-1-0-dodecyl-propan-1.2-diol-2-0-phosphocholine
 3-Amino-1-0-tridecyl-propan-1.2-diol-2-0-phosphocholine
 3-Amino-1-0-tetradecyl-propan-1.2-diol-2-0-phosphocholine
 3-Amino-1-0-pentadecyl-propan-1.2-diol-2-0-phosphocholine
 3-Amino-1-0-hexadecyl-propan-1.2-diol-2-0-phosphocholine
 3-Amino-1-0-heptadecyl-propan-1.2-diol-2-0-phosphocholine
 3-Amino-1-0-octadecyl-propan-1.2-diol-2-0-phosphocholine
 3-Amino-1-0-nonadecyl-propan-1.2-diol-2-0-phosphocholine
 3-Amino-1-0-eicosyl-propan-1.2-diol-2-0-phosphocholine
 1-0-Decyl-3-methylamino-propan-1.2-diol-2-0-phosphocholine
 1-0-Dodecyl-3-methylamino-propan-1.2-diol-2-0-phosphocholine
 3-Methylamino-1-0-tetradecyl-propan-1.2-diol-2-0-phosphocholine
 1-0-Hexadecyl-3-methylamino-propan-1.2-diol-2-0-phosphocholine

- 1 3-Methylamino-1-0-octadecyl-propan-1.2-diol-2-0-phospho-
choline
1-0-Eicosyl-3-methylamino-propan-1.2-diol-2-0-phosphocho-
line
- 5 1-0-Decyl-3-ethylamino-propan-1.2-diol-2-0-phosphocholine
1-0-Dodecyl-3-ethylamino-propan-1.2-diol-2-0-phosphocholine
3-Ethylamino-1-0-tetradecyl-propan-1.2-diol-2-0-phospho-
choline
3-Ethylamino-1-0-hexadecyl-propan-1.2-diol-2-0-phosphocho-
line
- 10 3-Ethylamino-1-0-octadecyl-propan-1.2-diol-2-0-phosphocho-
line
1-0-Eicosyl-3-ethylamino-propan-1.2-diol-2-0-phosphocholine
1-0-Decyl-3-hexadecylamino-propan-1.2-diol-2-0-phosphocho-
line
- 15 1-0-Dodecyl-3-hexadecylamino-propan-1.2-diol-2-0-phospho-
choline
3-Hexadecylamino-1-0-tetradecyl-propan-1.2-diol-2-0-phos-
phocholine
- 20 1-0-Hexadecyl-3-hexadecylamino-propan-1.2-diol-2-0-phos-
phocholine
3-Hexadecylamino-1-0-octadecyl-propan-1.2-diol-2-0-phos-
phocholine
1-0-Eicosyl-3-hexadecylamino-propan-1.2-diol-2-0-phospho-
choline
- 25 1-0-Decyl-3-octadecylamino-propan-1.2-diol-2-0-phosphocho-
line
1-0-Dodecyl-3-octadecylamino-propan-1.2-diol-2-0-phospho-
choline
- 30 3-Octadecylamino-1-0-tetradecyl-propan-1.2-diol-2-0-phos-
phocholine
1-0-Octadecyl-3-octadecylamino-propan-1.2-diol-2-0-phos-
phocholine
1-0-Eicosyl-3-octadecylamino-propan-1.2-diol-2-0-phospho-
choline
- 35 1-0-Decyl-3-eicosylamino-propan-1.2-diol-2-0-phosphocho-
line

- 1 1-0-Dodecyl-3-eicosylamino-propan-1.2-diol-2-0-phosphocholine
- 3-Eicosylamino-1-0-tetradecyl-propan-1.2-diol-2-0-phosphocholine
- 5 3-Eicosylamino-1-0-octadecyl-propan-1.2-diol-2-0-phosphocholine
- 1-0-Eicosyl-3-eicosylamino-propan-1.2-diol-2-0-phosphocholine
- 3-Benzylamino-1-0-decyl-propan-1.2-diol-2-0-phosphocholine
- 10 3-Benzylamino-1-0-dodecyl-propan-1.2-diol-2-0-phosphocholine
- 3-Benzylamino-1-0-tetradecyl-propan-1.2-diol-2-0-phosphocholine
- 3-Benzylamino-1-0-hexadecyl-propan-1.2-diol-2-0-phosphocholine
- 15 3-Benzylamino-1-0-octadecyl-propan-1.2-diol-2-0-phosphocholine
- 3-Benzylamino-1-0-eicosyl-propan-1.2-diol-2-0-phosphocholine
- 1-0-Hexadecyl-3-phenylamino-propan-1.2-diol-2-0-phosphocholine
- 20 1-0-Octadecyl-3-phenylamino-propan-1.2-diol-2-0-phosphocholine
- 3-Acetylamino-1-0-decyl-propan-1.2-diol-2-0-phosphocholine
- 3-Acetylamino-1-0-dodecyl-propan-1.2-diol-2-0-phosphocholine
- 25 3-Acetylamino-1-0-tetradecyl-propan-1.2-diol-2-0-phosphocholine
- 3-Acetylamino-1-0-hexadecyl-propan-1.2-diol-2-0-phosphocholine
- 30 3-Acetylamino-1-0-octadecyl-propan-1.2-diol-2-0-phosphocholine
- 3-Acetylamino-1-0-eicosyl-propan-1.2-diol-2-0-phosphocholine
- 3-Butyrylamino-1-0-hexadecyl-propan-1.2-diol-2-0-phosphocholine
- 35 3-Butyrylamino-1-0-octadecyl-propan-1.2-diol-2-0-phosphocholine

- 1 3-Butyrylamino-1-0-eicosyl-propan-1.2-diol-2-0-phosphocholine
1-0-Hexadecyl-3-palmitoylamino-propan-1.2-diol-2-0-phosphocholine
- 5 1-0-Octadecyl-3-palmitoylamino-propan-1.2-diol-2-0-phosphocholine
1-0-Eicosyl-3-palmitoylamino-propan-1.2-diol-2-0-phosphocholine
1-0-Hexadecyl-3-stearoylamino-propan-1.2-diol-2-0-phosphocholine
- 10 1-0-Octadecyl-3-stearoylamino-propan-1.2-diol-2-0-phosphocholine
1-0-Eicosyl-3-stearoylamino-propan-1.2-diol-2-0-phosphocholine
- 15 1-0-Hexadecyl-3-methoxycarbonylamino-propan-1.2-diol-2-0-phosphocholine
3-Methoxycarbonylamino-1-0-octadecyl-propan-1.2-diol-2-0-phosphocholine
1-0-Eicosyl-3-methoxycarbonylamino-propan-1.2-diol-2-0-phosphocholine
- 20 3-Ethoxycarbonylamino-1-0-hexadecyl-propan-1.2-diol-2-0-phosphocholine
3-Ethoxycarbonylamino-1-0-octadecyl-propan-1.2-diol-2-0-phosphocholine
- 25 1-0-Eicosyl-3-ethoxycarbonylamino-propan-1.2-diol-2-0-phosphocholine
3-Benzyloxycarbonylamino-1-0-hexadecyl-propan-1.2-diol-2-0-phosphocholine
3-Benzyloxycarbonylamino-1-0-octadecyl-propan-1.2-diol-2-0-phosphocholine
- 30 3-Benzyloxycarbonylamino-1-0-eicosyl-propan-1.2-diol-2-0-phosphocholine
1-0-Hexadecyl-3-ureido-propan-1.2-diol-2-0-phosphocholine
1-0-Octadecyl-3-ureido-propan-1.2-diol-2-0-phosphocholine
- 35 1-0-Eicosyl-3-ureido-propan-1.2-diol-2-0-phosphocholine
1-0-Hexadecyl-3-(3-methylureido)-propan-1.2-diol-2-0-phosphocholine

- 1 3-(3-Methylureido)-1-0-octadecyl-propan-1,2-diol-2-0-phosphocholine
1-0-Eicosyl-3-(3-methylureido)-propan-1,2-diol-2-0-phosphocholine
- 5 3-(3-Ethylureido)-1-0-hexadecyl-propan-1,2-diol-2-0-phosphocholine
3-(3-Ethylureido)-1-0-octadecyl-propan-1,2-diol-2-0-phosphocholine
1-0-Eicosyl-3-(3-ethylureido)-propan-1,2-diol-2-0-phosphocholine
- 10 1-0-Hexadecyl-3-(3-hexadecylureido)-propan-1,2-diol-2-0-phosphocholine
3-(3-Hexadecylureido)-1-0-octadecyl-propan-1,2-diol-2-0-phosphocholine
- 15 1-0-Eicosyl-3-(3-hexadecylureido)-propan-1,2-diol-2-0-phosphocholine
3-(3,3-Dimethylureido)-1-0-hexadecyl-propan-1,2-diol-2-0-phosphocholine
3-(3,3-Dimethylureido)-1-0-octadecyl-propan-1,2-diol-2-0-phosphocholine
- 20 3-(3,3-Dimethylureido)-1-0-eicosyl-propan-1,2-diol-2-0-phosphocholine
3-(3-Benzylureido)-1-0-hexadecyl-propan-1,2-diol-2-0-phosphocholine
- 25 3-(3-Benzylureido)-1-0-octadecyl-propan-1,2-diol-2-0-phosphocholine
3-(3-Benzylureido)-1-0-eicosyl-propan-1,2-diol-2-0-phosphocholine
3-(N-Acetyl-methylamino)-1-0-hexadecyl-propan-1,2-diol-2-0-phosphocholine
- 30 3-(N-Acetyl-methylamino)-1-0-octadecyl-propan-1,2-diol-2-0-phosphocholine
3-(N-Acetyl-methylamino)-1-0-eicosyl-propan-1,2-diol-2-0-phosphocholine
- 35 3-(N-Acetyl-methylamino)-1-0-oleyl-propan-1,2-diol-2-0-phosphocholine
3-(N-Acetyl-methylamino)-1-0-linolyl-propan-1,2-diol-2-0-phosphocholine

- 1 3-(N-Benzoyl-methylamino)-1-0-hexadecyl-propan-1.2-diol-
2-0-phosphocholin
3-(N-Benzoyl-methylamino)-1-0-octadecyl-propan-1.2-diol-
2-0-phosphocholin
- 5 3-(N-Benzoyl-methylamino)-1-0-eicosyl-propan-1.2-diol-2-0-
phosphocholine
3-(N-Benzoyl-methylamino)-1-0-oleyl-propan-1.2-diol-2-0-
phosphocholine
3-(N-Benzoyl-methylamino)-1-0-linoly-propan-1.2-diol-2-0-
10 phosphocholine
3-[N-(4-Chlorobenzoyl)-methylamino]-1-0-hexadecyl-propan-1.2-
diol-2-0-phosphocholine
1-0-Hexadecyl-3-[N-(4-methoxybenzoyl)-methylamino]-propan-
1.2-diol-2-0-phosphocholine
- 15 1-0-Hexadecyl-3-[N-(4-methylbenzoyl)-methylamino]-propan-
1.2-diol-2-0-phosphocholine
3-[N-(4-Ethoxybenzoyl)-methylamino]-1-0-hexadecyl-propan-
1.2-diol-2-0-phosphocholine
1-0-Hexadecyl-3-[N-(3-trifluormethylbenzoyl)-methylamino]-
20 propan-1.2-diol-2-0-phosphocholine
3-(N-Acetyl-hexadecylamino)-1-0-hexadecyl-propan-1.2-diol-
2-0-phosphocholine
3-(N-Acetyl-hexadecylamino)-1-0-octadecyl-propan-1.2-diol-
2-0-phosphocholine
- 25 3-(N-Acetyl-hexadecylamino)-1-0-eicosyl-propan-1.2-diol-
2-0-phosphocholine
3-(N-Acetyl-benzylamino)-1-0-hexadecyl-propan-1.2-diol-2-0-
phosphocholine
3-(N-Acetyl-benzylamino)-1-0-octadecyl-propan-1.2-diol-2-0-
30 phosphocholine
3-(N-Acetyl-benzylamino)-1-0-eicosyl-propan-1.2-diol-2-0-
phosphocholine
1-0-Hexadecyl-3-(N-methyl-palmitoylamino)-propan-1.2-diol-
2-0-phosphocholine
- 35 3-(N-Methyl-palmitoylamino)-1-0-octadecyl-propan-1.2-diol-
2-0-phosphocholine

- 1 1-O-Eicosyl-3-(N-methyl-palmitoylamino)-propan-1,2-diol-2-0-phosphocholine
- 3-(N-Methyl-palmitoylamino)-1-0-oleyl-propan-1,2-diol-2-0-phosphocholine
- 5 3-(N-Methyl-oleoylamino)-1-0-oleyl-propan-1,2-diol-2-0-phosphocholine
- 1-0-Hexadecyl-3-(N-octadecyl-oleoylamino)-propan-1,2-diol-2-0-phosphocholine
- 3-(N-Ethoxycarbonyl-methylamino)-1-0-hexadecyl-propan-1,2-
- 10 diol-2-0-phosphocholine
- 3-(N-Ethoxycarbonyl-methylamino)-1-0-octadecyl-propan-1,2-diol-2-0-phosphocholine
- 1-0-Eicosyl-3-(N-ethoxycarbonyl-methylamino)-propan-1,2-diol-2-0-phosphocholine
- 15 3-(N-Benzyloxycarbonyl-methylamino)-1-0-hexadecyl-propan-1,2-diol-2-0-phosphocholine
- 3-(N-Benzyloxycarbonyl-methylamino)-1-0-octadecyl-propan-1,2-diol-2-0-phosphocholine
- 3-(N-Benzyloxycarbonyl-methylamino)-1-0-eicosyl-propan-
- 20 1,2-diol-2-0-phosphocholine
- 3-(N-Benzyloxycarbonyl-hexadecylamino)-1-0-hexadecyl-propan-1,2-diol-2-0-phosphocholine
- 3-(N-Benzyloxycarbonyl-hexadecylamino)-1-0-octadecyl-propan-1,2-diol-2-0-phosphocholine
- 25 3-(N-Benzyloxycarbonyl-hexadecylamino)-1-0-eicosyl-propan-1,2-diol-2-0-phosphocholine
- 3-(N-Benzyloxycarbonyl-octadecylamino)-1-0-hexadecyl-propan-1,2-diol-2-0-phosphocholine
- 3-(N-Benzyloxycarbonyl-octadecylamino)-1-0-octadecyl-propan-
- 30 1,2-diol-2-0-phosphocholine
- 3-(N-Benzyloxycarbonyl-octadecylamino)-1-0-eicosyl-propan-1,2-diol-2-0-phosphocholine
- 3-(N-Benzyloxycarbonyl-eicosylamino)-1-0-hexadecyl-propan-1,2-diol-2-0-phosphocholine
- 35 3-(N-Benzyloxycarbonyl-eicosylamino)-1-0-octadecyl-propan-1,2-diol-2-0-phosphocholine
- 3-(N-Benzyloxycarbonyl-eicosylamino)-1-0-eicosyl-propan-1,2-diol-2-0-phosphocholine

- 1 3-(N-Benzyl-benzyloxycarbonylamino)-1-0-hexadecyl-propan-
1.2-diol-2-0-phosphocholine
3-(N-Benzyl-benzyloxycarbonylamino)-1-0-octadecyl-propan-
1.2-diol-2-0-phosphocholine
- 5 3-(N-Benzyl-benzyloxycarbonylamino)-1-0-eicosyl-propan-1.2-
diol-2-0-phosphocholine
3-(N-Benzyl-benzyloxycarbonylamino)-1-0-oleyl-propan-1.2-
diol-2-0-phosphocholine
1-0-Hexadecyl-3-(1-methylureido)-propan-1.2-diol-2-0-phos-
10 phocholine
3-(1-Methylureido)-1-0-octadecyl-propan-1.2-diol-2-0-phos-
phocholine
1-0-Eicosyl-3-(1-methylureido)-propan-1.2-diol-2-0-phos-
phocholine
- 15 3-(1-Ethylureido)-1-0-hexadecyl-propan-1.2-diol-2-0-phos-
phocholine
3-(1-Ethylureido)-1-0-octadecyl-propan-1.2-diol-2-0-phos-
phocholine
1-0-Eicosyl-3-(1-ethylureido)-propan-1.2-diol-2-0-phospho-
20 choline
1-0-Hexadecyl-3-(1-hexadecylureido)-propan-1.2-diol-2-0-
phosphocholine
3-(1-Hexadecylureido)-1-0-octadecyl-propan-1.2-diol-2-0-
phosphocholine
- 25 1-0-Eicosyl-3-(1-hexadecylureido)-propan-1.2-diol-2-0-phos-
phocholine
3-(1,3-Dimethylureido)-1-0-hexadecyl-propan-1.2-diol-2-0-
phosphocholine
3-(1,3-Dimethylureido)-1-0-octadecyl-propan-1.2-diol-2-0-
30 phosphocholine
3-(1,3-Dimethylureido)-1-0-eicosyl-propan-1.2-diol-2-0-
phosphocholine
3-(1-Benzylureido)-1-0-hexadecyl-propan-1.2-diol-2-0-phos-
phocholine
- 35 3-(1-Benzylureido)-1-0-octadecyl-propan-1.2-diol-2-0-phos-
phocholine
3-(1-Benzylureido)-1-0-eicosyl-propan-1.2-diol-2-0-phos-
phocholine

- 1 1-0-Hexadecyl-3-(1-hexadecyl-3-methylureido)-propan-1.2-diol-
2-0-phosphocholine
3-(1-Hexadecyl-3-methylureido)-1-0-octadecyl-propan-1.2-diol-
2-0-phosphocholine
- 5 1-0-Eicosyl-3-(1-hexadecyl-3-methylureido)-propan-1.2-diol-
2-0-phosphocholine
1-0-Hexadecyl-3-(3-methyl-1-octadecylureido)-propan-1.2-diol-
2-0-phosphocholine
3-(3-Methyl-1-octadecylureido)-1-0-octadecyl-propan-1.2-diol-
10 2-0-phosphocholine
1-0-Eicosyl-3-(3-methyl-1-octadecylureido)-propan-1.2-diol-
2-0-phosphocholine
3-(3-Ethyl-1-hexadecylureido)-1-0-hexadecyl-propan-1.2-diol-
2-0-phosphocholine
- 15 3-(3-Ethyl-1-hexadecylureido)-1-0-octadecyl-propan-1.2-diol-
2-0-phosphocholine
1-0-Eicosyl-3-(3-ethyl-1-hexadecylureido)-propan-1.2-diol-
2-0-phosphocholine
1-0-Hexadecyl-3-(1-hexadecyl-3-phenylureido)-propan-1.2-
20 diol-2-0-phosphocholine
3-[3-(4-chlorophenyl)-1-hexadecylureido]-1-0-hexadecyl-propan-
1.2-diol-2-0-phosphocholine
3-(1-Hexadecyl-3-phenylureido)-1-0-octadecyl-propan-1.2-diol-
2-0-phosphocholine
- 25 1-0-Eicosyl-3-(1-hexadecyl-3-phenylureido)-propan-1.2-diol-
2-0-phosphocholine
1-0-Hexadecyl-3-(3-phenylureido)-propan-1.2-diol-2-0-phos-
phocholine
1-0-Octadecyl-3-(3-phenylureido)-propan-1.2-diol-2-0-phos-
30 phocholine
1-0-Eicosyl-3-(3-phenylureido)-propan-1.2-diol-2-0-phospho-
choline
3-[3-(4-chlorophenyl)-ureido]-1-0-hexadecyl-propan-1.2-diol-
2-0-phosphocholine
- 35 3-[3-(4-chlorophenyl)-ureido]-1-0-octadecyl-propan-1.2-diol-
2-0-phosphocholine

- 1 3-[3-(4-chlorophenyl)-ureido]-1-0-eicosyl-propan-1.2-diol-
2-0-phosphocholine
1-0-Hexadecyl-3-[3-(2-phenylethyl)-ureido]-propan-1.2-diol-
2-0-phosphocholine
- 5 1-0-Octadecyl-3-[3-(2-phenylethyl)-ureido]-propan-1.2-diol-
2-0-phosphocholine
1-0-Eicosyl-3-[3-(2-phenylethyl)-ureido]-propan-1.2-diol-
2-0-phosphocholine
1-0-Hexadecyl-3-(2-phenylethylamino)-propan-1.2-diol-2-0-
10 phosphocholine
1-0-Octadecyl-3-(2-phenylethylamino)-propan-1.2-diol-2-0-
phosphocholine
1-0-Eicosyl-3-(2-phenylethylamino)-propan-1.2-diol-2-0-
phosphocholine
- 15 3-(N-Acetyl-2-phenylethylamino)-1-0-hexadecyl-propan-1.2-
diol-2-0-phosphocholine
3-(N-Acetyl-2-phenylethylamino)-1-0-octadecyl-propan-1.2-
diol-2-0-phosphocholine
3-(N-Acetyl-2-phenylethylamino)-1-0-eicosyl-propan-1.2-diol-
20 2-0-phosphocholine
3-(N-Acetyl-2-phenylethylamino)-1-0-oleyl-propan-1.2-diol-
2-0-phosphocholine
[1-(N-Acetyl-aminomethyl)-2-hexadecyloxy-ethyl]-3-trimethyl-
ammoniopropyl-phosphate
- 25 [1-(N-Acetyl-aminomethyl)-2-hexadecyloxy-ethyl]-4-trimethyl-
ammoniobutyl-phosphate
[1-(N-Acetyl-methylaminomethyl)-2-hexadecyloxy-ethyl]-3-
trimethylammoniopropyl-phosphate
[1-(N-Acetyl-methylaminomethyl)-2-hexadecyloxy-ethyl]-4-
30 trimethylammoniobutyl-phosphate
[1-(N-Acetyl-aminomethyl)-2-octadecyloxy-ethyl]-3-trimethyl-
ammoniopropyl-phosphate
[1-(N-Acetyl-aminomethyl)-2-octadecyloxy-ethyl]-4-trime-
thylammoniobutyl-phosphate
- 35 [1-(N-Acetyl-methylaminomethyl)-2-octadecyloxy-ethyl]-3-
trimethylammoniopropyl-phosphate

- [1-(N-Acetyl-methylaminomethyl)-2-octadecyloxy-ethyl]-4-trimethylammonioethyl-phosphate
- [1-(N-Acetyl-aminomethyl)-2-hexadecyloxy-ethyl]-2-dimethylammonioethyl-phosphate
- 5 [1-(N-Acetyl-methylaminomethyl)-2-hexadecyloxy-ethyl]-2-dimethylammonioethyl-phosphate
- [1-(N-Acetyl-aminomethyl)-2-octadecyloxy-ethyl]-2-dimethylammonioethyl-phosphate
- [1-(N-Acetyl-methylaminomethyl)-2-octadecyloxy-ethyl]-2-dimethylammonioethyl-phosphate
- 10 [1-(N-Acetyl-aminomethyl)-2-hexadecyloxy-ethyl]-2-butyl-dimethylammonioethyl-phosphate
- [1-(N-Acetyl-aminomethyl)-2-octadecyloxy-ethyl]-2-butyl-dimethylammonioethyl-phosphate.

- 15 Depending upon the fact whether there has been effected a split of racemates, the above compounds may be present in their R- or S-form or as racemate mixture.

The compounds of the present invention are biologically very active and may be used for instance in drugs or in plant protection. Thus, they may be used for the treatment of high blood pressure, and for the therapy of cancer.

20

For preparing the new 1-O-alkyl-3-amino-propane-1,2-diol-2-O-phospholipids, 2,3-epoxypropylethers of formula $R^1-OCH_2-\overset{O}{\underset{\text{CH}_2}{\text{C}}}$ (regarding their production see E. Mouzin et al., Synthesis


25 1983, 117 and following) are subjected to reaction with the corresponding amine of formula $\text{HN} \begin{matrix} / \text{R}^5 \\ \backslash \text{R}^6 \end{matrix}$ corresponding to the procedure as known for epoxides (see for instance Houben-Weyl, Methoden der organischen Chemie, 4. Ed., Vol. 11/1, p. 314 and following, Georg Thieme Verlag, Stuttgart 1957) to yield

30 the corresponding substituted 3-amino-2-hydroxy-propylethers and, if desired, to subject them to N-acylation by usual methods. The starting materials II

- 13 -



wherein R^1 , R^5 and R^6 have the same meaning as in formula I, resulting therefrom are subjected to reaction with dichloro-phosphoric acid- ω -halogene alkyl esters of formula III



wherein n has the same meaning as in formula I and Hal is a chlorine or bromine atom, in an inert organic solvent, possibly with the addition of an auxiliary base such as pyridine or triethylamine, the resulting compounds subsequently being reacted with an amine of formula IV



wherein R^2 , R^3 and R^4 have the same meaning as in formula I in an inert organic solvent such as toluene, dioxane, tetrahydrofuran, possibly with the application of pressure (regarding thereto, see: H.K. Mangold, *Angew. Chemie* 91, 550 to 560 (1979; H. Eibl, *Chem. and Phys. of Lipids* 26, 405 to 429 (1980)).

If the resulting compounds of formula I have benzyl, benzyl-oxycarbonyl or similar protective groups, these groups may be split-off by hydrogenation under usual conditions in the presence of heavy metal catalysts and hydrogen, thus forming compounds of formula I wherein R^5 and/or R^6 is hydrogen.

On the other side, a compound of formula I wherein R⁵ and/or R⁶ is hydrogen may be subjected to reaction, in the presence of a suitable condensation agent such as thionylchloride, carbonylbisimidazol, carbodiimides and the like, with an acid of formula V



wherein m and R⁷ have the same meaning as in formula I, or, possibly in the presence of auxiliary basis such as triethylamine, pyridine and the like, with an acid derivative of formula VI



wherein A, m and R⁷ have the same meaning as in formula I (with the exception of A representing a bond) and Hal is a halogen atom or an acid anhydride group, in particular a chloro or a bromo atom. Acylation may also be effected with isocyanates of formula VII



wherein R⁵ has the same meaning as in formula I, possibly with the addition of catalysts such as dimethylformamide or 4-dimethylaminopyridine.

The starting compounds of formula II may be used in their R- or S-form or as racemate; accordingly, there are obtained the R- or S-forms or racemate mixtures of the final products I.

The present invention is further related to pharmaceutical preparations which contain the 1-O-alkyl-3-amino-propan-1,2-diol-2-O-phospholipids of formula I. The pharmaceutical preparations according to the present invention are products for enteral as oral or rectal as well as parenteral application. They contain the pharmaceutically active agents

alone or together with usual, pharmaceutically applicable carrier materials. Preferably, the pharmaceutical preparations of the active agent are in the form of single doses corresponding to the desired form of application such as
5 tablets, dragees, capsules, suppositories, granulates, solutions, emulsions or suspensions. The dosages of the compounds usually are between 1 and 1000 mg. per day, preferably between 10 and 100 mg. per day, and the product may be administered once or several times, preferably between
10 two and three times, per day.

The preparation of the compounds according to the present invention are further illustrated by the following examples. The reported melting points have been determined by means of a Büchi 510 melting point apparatus and they are not
15 corrected. The infrared spektra have been determined in a Perkin-Elmer 257 or Nicolet NIC-3600 type apparatus.

Example 1

3-(N-acetyl-methylamino)-1-O-hexadecyl-propan -1,2-diol-2-O-phosphocholine.

20 a) 1-Hexadecyloxy-3-methylamino-propan-2-ol.

A cooled mixture of 15.5 g of methylamine, 50 cc. of tetrahydrofuran and 15 g of hexadecyl-2,3-epoxypropylether is heated to 60°C. for 2 hours in an autoclave, cooled and evaporated in a vacuo. The residue is purified by
25 column chromatography (silicic acid gel//chloroform/methanol).

Yield: 10.5 g F.: 89 to 91°C.

b) 3-(N-acetyl-methylamino)-1-hexadecyloxy-propan-2-ol.

5 g of 1-hexadecyloxy-3-methylamino-propan-2-ol are dissolved in 30 cc. of anhydrous chloroform. At first
30 3 g of triethylamine and separately thereafter 2.4 g of acetylchloride are added dropwise with cooling and the mixture is stirred for 8 hours. The chloroform solution

is washed with 2 % hydrochloric acid and water, is evaporated and the residue is dissolved in 100 cc. of methanol. A solution of 0.6 g of sodium hydroxide in a little methanol is added to the methanol solution and the mixture is stirred
5 at room temperature for one hour. The solvent is evaporated in a vacuo and the residue is triturated in chloroform. The chloroform solution is washed with 2 % hydrochloric acid and water, is dried over sodium sulfate and is evaporated.

Yield: 3.7 g of an oil

10 IR (film): 3350, 1630 1120 cm^{-1} .

c) [1-(N-acetyl-methylaminomethyl)-2-hexadecyloxyethyl]-2-bromoethyl phosphate.

3.3 g of 3-(N-acetyl-methylamino)-1-hexadecyloxy-propan-2-ol are dissolved in 100 cc. of anhydrous chloroform and the solution is added dropwise to a mixture of 4.3 g
15 of 2-bromoethylphosphoric acid dichloride, 10 cc. of chloroform and 50 cc. of pyridin cooled with ice. The resulting mixture is stirred for one hour at room temperature, diluted with water and stirred another hour at
20 room temperature. The organic phase is separated, washed with 5 % hydrochloric acid and water, dried over sodium sulfate and the solvent is separated in a vacuo. The residue is purified by column chromatography (silicic acid gel//chloroform/methanol).

25 Yield: 1.6 g of an oil.

d) 3-(N-acetyl-methylamino)-1-O-hexadecyl-propan -1,2-diol-2-O-phosphocholine.

1.6 g of [1-(N-acetyl-methylaminomethyl)-2-hexadecyloxyethyl]-2-bromoethyl phosphate are dissolved in 30 cc. of
30 anhydrous toluene. About 3 cc. of a 33 % solution of trimethylamine in ethanol is added thereto and the resulting mixture is stirred for 4 hours at 60°C. in a closed container. The solvent is evaporated in a vacuo and the residue is purified by column chromatography (silicic

acid gel//chloroform/methanol).

Yield: 0.4 g of a waxy product

IR (film): 1635 cm^{-1} .

Example 2

5 3-(N-benzyl-benzyloxycarbonylamino)-1-O-hexadecyl-propan-
1.2-diol-2-O-phosphocholine.

a) 3-Benzylamino-1-hexadecyloxy-propan-2-ol.

A mixture of 24.4 g of benzylamine, 100 cc. of tetrahydro-
furane and 34 g of hexadecyl-2.3-epoxypropylether is re-
10 fluxed for 8 hours and the solvent is evaporated in a
vacuo. The residue is recrystallized from hexane.

Yield: 30.8 g F.: 56 to 58°C.

b) 3-(N-benzyl-benzyloxycarbonylamino)-1-hexadecyloxy-propan-
2-ol.

15 21.4 g of 3-benzylamino-1-hexadecyloxy-propan-2-ol are
dissolved in 100 cc. of anhydrous chloroform. At first
5.4 g of triethylamine and then a solution of 9 g of
chloroformic acid benzyl ester in 50 cc. of chloroform
is added dropwise with cooling and the mixture is
20 stirred for 3 hours. The chloroform solution is washed
with 5 % hydrochloric acid and water, dried over sodium
sulfate, evaporated and the residue is purified by column
chromatography (silicic acid gel//chloroform).

Yield: 21 g (oil)

25 IR (film): 3445, 1701, 1125 cm^{-1} .

c) [1-(N-benzyl-benzyloxycarbonylaminoethyl)-2-hexadecyloxyethyl]-2-bromoethyl phosphate.

16 g of 3-(N-benzyl-benzyloxycarbonylamino)-1-hexadecyloxy-propan-2-ol are dissolved in 30 cc. of anhydrous chloroform and the solution is added dropwise to an ice-cooled mixture of 14.5 g of 2-bromoethylphosphoric acid dichloride, 120 cc. of chloroform and 9.5 g of pyridine. The mixture is stirred for 1 hour at room temperature, diluted with water and again stirred for 1 hour at room temperature. The organic phase is separated, washed with 5 % hydrochloric acid and water, dried over sodium sulfate and the solvent is evaporated in a vacuo. The residue is purified by column chromatography (silicic acid gel//chloroform/methanol).

Yield: 11.8 g (oil).

d) 3-(N-benzyl-benzyloxycarbonylamino)-1-O-hexadecyl-propan-1,2-diol-2-O-phosphocholine.

11.5 g of [1-(N-benzyl-benzyloxycarbonylaminoethyl)-2-hexadecyloxyethyl]-2-bromoethylphosphate are dissolved in 50 cc. of anhydrous toluene. About 10 cc. of a 33 % solution of trimethylamine in ethanol is added thereto and the mixture is stirred for 4 hours at 60°C. in a closed container. The solvent is evaporated in a vacuo and the residue is purified by column chromatography (silicic acid gel//chloroform/methanol).

Yield: 4.6 g of a waxy product

IR (film): 1696 cm^{-1} .

Example 3

3-Amino-1-O-hexadecyl-propan -1,2-diol-2-O-phosphocholine.

4.3 g of 3-(N-benzylbenzyloxycarbonylamino)-1-O-hexadecyl-
propan -1,2-diol-2-O-phosphocholine are dissolved in 200 cc.
5 of a 4:1 (v/v)-mixture of dioxane and water and, after the
addition of 0.43 g of palladium-active carbon, are hydrogen-
ated with hydrogen. The solution is filtered, the filter
residue is washed with ethanol, the filtrates are combined
and evaporated to dryness. The residue is purified by column
10 chromatography (silicic acid gel //chloroform/methanol/conc.
ammonia).

Yield: 1.4 g F.: 217 to 219°C.

Example 4

15 3-Benzylamino-1-O-hexadecyl-propan -1,2-diol-2-O-phospho-
choline as produced similarly to Example 3 by incomplete
hydrogenation.

For instance, there are isolated with the procedure des-
cribed in Example 3 0.3 g of waxy 3-benzylamino-1-O-hexa-
decyl-propan -1,2-diol-2-O-phosphocholine as side product.
20 With the same procedure there of course may be also pro-
duced the 3-alkylamino-, 3-arylamino- and 3-arylalkylamino-
compounds.

Example 5

3-Acetylamino-1-O-hexadecyl-propan -1.2-diol-2-O-phospho-
choline.

- 5 a) 0.35 g of 3-amino-1-O-hexadecyl-propan -1.2-diol-2-O-
phosphocholine are dissolved in 10 cc. of anhydrous
chloroform. 0.14 g of acetic acid anhydride are added
thereto and the mixture is stirred for about 12 hours
at room temperature. The solution is evaporated in a
vacuo and the residue is purified by column chromato-
10 graphy (silicic acid gel//chloroform/methanol/water).

Yield: 0.2 g F.: 237 to 239°C.

IR (in KBr): 1667 cm^{-1} .

- 15 b) 0.24 g of 3-amino-1-O-hexadecyl-propan -1.2-diol-2-O-
phosphocholine are dissolved in 5 cc. of anhydrous
chloroform. 0.1 g of triethylamine and 0.08 g of acetyl-
chloride are added thereto and the mixture is stirred
for about 12 hours at room temperature. The solution is
evaporated in a vacuo and the residue is purified by
column chromatography (silicic acid gel//chloroform/
20 methanol/water).

Yield: 0.18 g

Example 6


1-O-Hexadecyl-3-(3-methylureido)-propan -1.2-diol-2-O-phospho-
choline.

- 25 0.48 g of 3-amino-1-O-hexadecyl-propan -1.2-diol-2-O-phospho-
choline are dissolved in 10 cc. of anhydrous chloroform. 0.17 g
of methylisocyanate are added to this solution and the mixture
is stirred for 12 hours at room temperature. The solution is
evaporated in a vacuo and the residue is purified by column
30 chromatography (Silicic acid gel//chloroform/methanol/water).

Yield: 0.4 g F.: 243 to 245°C.

Patent claims

1. 1-O-Alkyl-3-amino-propan-1,2-diol-2-O-phospholipids and their derivatives of the formula I



wherein


- 5 R^1 is a saturated or unsaturated, straight-chain or branched alkyl group with 10 to 20 carbon atoms,
- R^2, R^3
and R^4 which may be the same or different, represent
10 hydrogen or a lower alkyl group with 1 to 4 carbon atoms,
- R^5 and R^6 which may be the same or different, represent
hydrogen or the group $-\text{A}-\text{C}_m\text{H}_{2m}-\text{R}^7$ or $-\text{A}-\text{C}_m\text{H}_{2m-2}-\text{R}^7$,
- 15 R^7 is hydrogen, unsubstituted phenyl or phenyl substituted by a C_{1-3} -alkyl, C_{1-3} -alkoxy, trifluoromethyl group, or a halogen atom,
- A is a bond, $-\text{CO}-$, $-\text{COO}-$ or $-\text{CONR}^8-$,
 R^8 is hydrogen or C_{1-4} -alkyl,
- m is a numeral from 0 to 20 and
- 20 n is a numeral from 2 to 4.

2. 1-O-Alkyl-3-amino-propan-1,2-diol-2-O-phospholipids of the general formula I according to claim 1 wherein

- 25 R^1 is a saturated or unsaturated, straight-chain alkyl group with 10 to 20 carbon atoms,

- R^2 , R^3
 and R^4 which may be the same or different, represent
 hydrogen or methyl,
 R^5 and
 5 R^6 which may be the same or different, represent
 hydrogen or the group $-A-(CH_2)_m-R^7$,
 R^7 is hydrogen, unsubstituted phenyl or phenyl sub-
 stituted by a methyl, methoxy, halogen, trifluoro-
 methyl group,
 10 A is a bond, $-CO-$, $-COO-$ or $-CONR^8-$,
 R^8 is hydrogen or C_{1-4} -alkyl,
 m is a numeral from 0 to 20, if R^7 is hydrogen, or
 is a numeral from 0 to 2, if R^7 is phenyl or sub-
 stituted phenyl and
 15 n is 2.


3. Process for producing the compounds of formula I
 according to claims 1 and 2 characterized in that
 2.3-epoxypropylether of formula $R^1OCH_2-\overset{O}{\text{C}}-\text{CH}_2$ wherein
 R^1 has the same meaning as in formula I, is subjected
 20 to reaction with an amine of formula $\begin{matrix} R^5 \\ \diagup \\ \text{HN} \\ \diagdown \\ R^6 \end{matrix}$ wherein R^5 and
 R^6 have the same meaning as in formula I, and possibly
 subsequent N-acylation to the starting compounds of the
 formula II



II

- 25 wherein R^1 , R^5 and R^6 have the same meaning as in formula
 I, and subjecting the same to reaction with a dichloro-
 phosphoric acid- ω -halogeno alkyl ester of formula III

- 3 -



wherein n has the same meaning as in formula I and Hal is a chlorine or bromine atom,

5 in an inert organic solvent, possibly with the use of an auxiliary base, and subsequent reaction with an amine of formula IV




10 wherein R², R³ and R⁴ have the same meaning as in formula I, in an inert organic solvent, possibly with the application of pressure.

4. Process for the preparation of compounds of formula I wherein R⁵ and/or R⁶ are hydrogen according to claims 1 or 2 characterized in that a compound of formula I wherein one or both of R⁵ and/or R⁶ represent a benzyl or benzyloxycarbonyl group, is subjected to hydration in an inert solvent in the presence of a usual catalyst for hydration.

15 5. Process for the production of compounds of formula I according to claims 1 or 2 characterized in that a compound of formula I with R⁵ and/or R⁶ are hydrogen, is subjected to reaction with an acid of formula V



25 wherein m and R⁷ have the same meaning as in formula I, in the presence of suitable condensation agents or, possibly in the presence of auxiliary bases, with an acid derivative of formula VI



VI

5 wherein A, m and R⁷ have the same meaning as in formula I, except A representing a bond, and Hal is a halogen atom or an acid anhydride group, or, possibly with the addition of a Lewis-base as catalyst, is subjected to reaction with an isocyanate of formula VII



VII

wherein R⁵ has the same meaning as in formula I, at the 3-amino group.

- 10 6. Pharmaceutical preparations characterized in that they contain a compound of general formula I according to claims 1 and 2 as active agent mixed with usual pharmaceutical auxiliary and carrier agents.

0130527



European Patent
Office

EUROPEAN SEARCH REPORT

Application number

EP 84 10 7293

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 7)
A	GB-A-2 020 663 (NATTERMANN)	1	C 07 F 9/10 A 61 K 31/685
A, P	<p style="text-align: center;">---</p> EP-A-0 092 190 (FUJISAWA PHARMACEUTICAL) <p style="text-align: center;">-----</p>	1	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 7)
			C 07 F 9/10
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 14-09-1984	Examiner KAPTEYN H G
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>			